Client & Alumni News

Azevan Pharmaceuticals Advances Study of Drug for Intermittent Explosive Disorder

Azevan Pharmaceuticals, Inc. (, which is developing novel small molecule medicines for disorders of stress, mood, and behavior, announced that enrollment has been completed in a Phase 2 clinical study of the company’s lead compound SRX246 in adults with DSM-5 Intermittent Explosive Disorder. Read more: